Medical Condition News

RSS

First group of patients 'graduate' from treatment at CDH Proton Center, A Procure Center

Two months after the opening of the CDH Proton Center, A ProCure Center, the first patients have "graduated" from their treatment surrounded by family, friends and staff. The group of graduating patients, whose tumors included prostate, brain and a non-cancerous tumor on the spinal cord, received proton therapy, an alternative to standard X-ray radiation that spares healthy tissue and results in far fewer short- and long-term treatment side effects.

20 Jan 2011

Researchers identify PBRM1 gene mutation in one in three patients with common form of renal cancer

In a collaborative project involving scientists from three continents, researchers have identified a gene that is mutated in one in three patients with the most common form of renal cancer.

20 Jan 2011

Eating more fruits and vegetables may reduce risk of heart disease: New Study

New research indicates that eating more fruits and vegetables may reduce your risk of dying from heart disease. According to a new study from the University of Oxford and published in the European Heart Journal, people who consumed eight or more servings of fruits and vegetables each day were 22 percent less likely to die from ischemic heart disease than those who consumed three or fewer servings a day.

20 Jan 2011

Children's Hospital Los Angeles becomes only Autism Treatment Network site in California

Following a competitive application process, Michele D. Kipke, PhD, Vice Chair of Research for the Department of Pediatrics, Children's Hospital Los Angeles, was awarded a $420,000 grant which will allow the hospital to become part of the Autism Treatment Network (ATN) as an ATN Center of Clinical Excellence.

20 Jan 2011

Adolescent girls may engage in substance use due to bullying-related depression

Both boys and girls who are victims of bullying, including bullying through e-mail and the internet, are at elevated risk for depression. However, according to a new study, adolescent girls may engage in substance use as a result of bullying-related depression.

20 Jan 2011

FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review

ADVENTRX Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has established a Prescription Drug User Fee Act (PDUFA) date of September 1, 2011 for the review of the Exelbine (ANX-530) New Drug Application (NDA).

20 Jan 2011

Researchers discover how Ras oncogene chooses a signaling pathway

The National Cancer Institute estimates that more than 43,000 Americans were diagnosed with pancreatic cancer last year and more than 36,000 died from the disease. Despite advances in genetic science showing that the Ras oncogene is mutated in virtually all pancreatic cancers, scientists have been frustrated by the complexity of the signaling pathways in humans, which make it difficult to pinpoint potential therapeutic targets.

20 Jan 2011

Biomarin commences BMN 701 Phase 1/2 trial for treatment of Pompe disease

BioMarin Pharmaceutical Inc. announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase in development for the treatment of Pompe disease.

20 Jan 2011

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Targacept, Inc. today announced positive top-line results from a Phase 2 clinical proof of concept trial to assess TC-5619 as an augmentation therapy to improve cognition in patients with schizophrenia.

20 Jan 2011

Study: HIV-positive head and neck cancer patients respond well to radiation therapy treatments

HIV-positive head and neck cancer patients respond well to radiation therapy treatments and experience similar toxicity rates as non-HIV-positive patients, despite prior reports to the contrary, according to a study in the January issue of the International Journal of Radiation Oncology•Biology•Physics, an official journal of the American Society for Radiation Oncology.

19 Jan 2011

Salk Institute uncovers presenilin's productive side

Mutant presenilin is infamous for its role in the most aggressive form of Alzheimer's disease-early-onset familial Alzheimer's-which can strike people as early as their 30s. In their latest study, researchers at the Salk Institute uncovered presenilin's productive side: It helps embryonic motor neurons navigate the maze of chemical cues that pull, push and hem them in on their way to their proper targets.

19 Jan 2011

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Neogenix Oncology announced today that Dr. Luis Diaz of The Johns Hopkins University Hospital will present data from Ensituximab, the company's novel, therapeutic antibody to treat pancreatic and colorectal cancers. The presentation is scheduled at the American Society of Clinical Oncology (ASCO) 2011 Gastrointestinal Cancers Symposium to be held January 20-22, 2011 at the Moscone Center in San Francisco, CA, USA.

19 Jan 2011

Novo Nordisk's new insulin pen for children receives 2010 GOOD DESIGN Award

A 2010 GOOD DESIGN Award has been awarded to Novo Nordisk for NovoPen Echo, the latest innovation in pen development - designed specifically with the needs of children in mind. Judging is made based on product design which is new, visionary and innovative and that may enrich people's lives.

From Novo Nordisk 19 Jan 2011

Theraclone, Pfizer enter multi-year research and development collaboration

Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, announced today that they have entered into a multi-year research and development collaboration with Pfizer. The collaboration will use Theraclone's I-STAR™ technology to discover broadly protective monoclonal antibodies against up to four undisclosed targets in the areas of infectious disease and cancer.

19 Jan 2011

Pisgah to scale-up patent-pending form of hydrocodone

As Pisgah Laboratories, Inc. continues development of its lead abuse deterrent opioid product, it will soon begin scale-up of its patent-pending form of hydrocodone. Pisgah has developed a specialized salt form of hydrocodone which imparts abuse deterrent properties to a dosage product. Pisgah will manufacture its hydrocodone salt for clinical trials in their FDA / DEA registered facility.

19 Jan 2011

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

Geron Corporation today announced enrollment of the first patient in a Phase 2 clinical trial to evaluate the activity of the company's telomerase inhibitor drug, imetelstat (GRN163L), in patients with essential thrombocythemia (ET).

19 Jan 2011

National Jewish Health issued method patent for desensitizing B cells

National Jewish Health has been issued a US patent claiming a method to desensitize B cells by inactivating antigen receptors on their surfaces. The method, discovered by John Cambier, PhD, Chairman of the Integrated Department of Immunology at National Jewish Health, holds promise for treatment of B-cell mediated diseases, such as lymphoma and leukemia, rheumatoid arthritis, lupus and rejection of organ transplants.

19 Jan 2011

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Pluristem Therapeutics, Inc. today announced the successful completion of a parallel scientific advisory process with the European Medical Agencies (EMA) and the U.S. Food and Drug Administration (FDA) regarding the Company's planned clinical development program for PLX-PAD.

19 Jan 2011

Transplant surgeons routinely use fewer organs from high-risk donors

As a response to a 2007 episode in which four patients in Chicago were transplanted with organs from a single donor unknowingly infected with HIV — the only such episode in 20 years — one-third of transplant surgeons in the United States "overreacted" and began routinely using fewer organs from high-risk donors, new research from Johns Hopkins finds.

19 Jan 2011

Three-stage approach to fMRI could improve detection of neural activity

Over the last few years, researchers have used a type of brain scanning, known as functional magnetic resonance imaging fMRI, to help them map changes in blood flow in the brain and to correlate this with thoughts and behavior. A new way to analyze fMRI data, which could improve is reported in the International Journal of Computational Biology and Drug Design.

19 Jan 2011

Medical Condition News

First group of patients 'graduate' from treatment at CDH Proton Center, A Procure Center

Researchers identify PBRM1 gene mutation in one in three patients with common form of renal cancer

Eating more fruits and vegetables may reduce risk of heart disease: New Study

Children's Hospital Los Angeles becomes only Autism Treatment Network site in California

Adolescent girls may engage in substance use due to bullying-related depression

FDA establishes PDUFA date for ADVENTRX's Exelbine NDA review

Researchers discover how Ras oncogene chooses a signaling pathway

Biomarin commences BMN 701 Phase 1/2 trial for treatment of Pompe disease

Positive top-line results from TC-5619 Phase 2 trial in patients with schizophrenia

Study: HIV-positive head and neck cancer patients respond well to radiation therapy treatments

Salk Institute uncovers presenilin's productive side

Data on Ensituximab for treatment of pancreatic and colorectal cancers to be presented at ASCO 2011

Novo Nordisk's new insulin pen for children receives 2010 GOOD DESIGN Award

Theraclone, Pfizer enter multi-year research and development collaboration

Pisgah to scale-up patent-pending form of hydrocodone

Geron commences enrollment in imetelstat Phase 2 clinical trial in essential thrombocythemia

National Jewish Health issued method patent for desensitizing B cells

Pluristem completes parallel scientific advisory process with EMA and FDA for PLX-PAD clinical development

Transplant surgeons routinely use fewer organs from high-risk donors

Three-stage approach to fMRI could improve detection of neural activity

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News